In vivo approach of simply constructed pyrazinamide conjugated chitosan-g-polycaprolactone micelles for methicillin resistance Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) is an extensive origin of nosocomial infections that are very much challenging as well as complicated to eradicate mostly due to their strong resistance against all existing antibiotic therapies. Here the chitosan-grafted-polycaprolactone/maleic anhydride-pyrazinamide (CS-g-PCL/MAPZA) polymeric drug carrier constructed via dialysis for anti-MRSA drugs like rifampicin (RF) and pyrazinamide (PZA) delivery. Nearly 200 nm size of the spherical particle with -20.04 mV of zeta potential observed. The cumulative PZA and RF releases from the carrier were observed 83.25% and 76.54% respectively in pH 5.5, and the in vitro drug release profile demonstrates that the fabricated micelle was pH-responsive. For the intestinal colonization, an in vivo assay performed using C. elegans, and the CS-g-PCL/MA-PZA/RF micelles treated worms generally belong to the weakly colonized category. Therefore, the study revealed that CS-g-PCL/MA-PZA/RF micelle could be a promising approach for therapeutic applications to achieve efficient anti-MRSA drug delivery. (c) 2020 Elsevier B.V. All rights reserved.